Haldor Topsøe has returned to participate in a $102m series C round for the cancer treatment developer.

US-based oncology-focused biotechnology developer IGM Biosciences received $102m in series C funding on Monday from investors including catalysis company Haldor Topsøe. Redmile Group, Janus Henderson Investors, Vivo Capital and an unnamed US-based healthcare-focused fund also contributed funding. Founded in 2010, IGM Biosciences is working on a treatment for cancer that relies on engineered immunoglobin M…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.